The effectiveness of an acceptance and commitment therapy based psychological intervention on reducing psychological distress in those diagnosed with gastro-intestinal dysmotility

ISRCTN ISRCTN79959493
DOI https://doi.org/10.1186/ISRCTN79959493
IRAS number 315811
Secondary identifying numbers CPMS 54458, IRAS 315811
Submission date
10/01/2023
Registration date
24/01/2023
Last edited
31/10/2024
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Digestive System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English Summary

Background and study aims
Gastrointestinal dysmotility (GID) describes an array of disorders which affect the movement of contents through the intestinal tract. At the severe end GID can lead to symptoms of pain, cramps, bloating, difficulty maintaining weight, constipation, diarrhoea, nausea, vomiting and malnutrition. It is often a cause of people needing long-term home intravenous feeding, known as home parenteral nutrition (HPN). Owing to the symptoms and treatment, it has been found that living with GID can have a significant detrimental impact on a person’s quality of life (QOL) and psychological wellbeing. A recent study reported that there is an increasing need for psychosocial support. However, there is limited data on what type of therapeutic modality or more so what component of the psychological intervention is most effective in the GID population. Acceptance and Commitment Therapy (ACT) has been found to be beneficial for psychological wellbeing in many other chronic conditions including IBD and applied in a group format. This study aims to assess the effectiveness, feasibility and acceptability of a group-based psychological intervention called ‘ACTing on your GUT feelings’.

Who can participate?
Patients aged over 18 years with GID

What does the study involve?
Participants will be randomly allocated to either the treatment group where they will attend seven 2-hour weekly sessions with an 8-week follow-up ‘reunion’, or a Treatment As Usual (waiting-list control) group. Both groups will be asked to complete a set of questionnaires. The questionnaires will collect demographic information and assess psychological wellbeing (anxiety and low mood), health-related quality of life and psychological flexibility (the ability to stay present with and adapt to the challenges of life). Medical outcomes will also be collected. All outcomes and questionnaires will be collected before and after the intervention. Participants will also be invited to attend interviews to discuss their views and experiences.

What are the possible benefits and risks of participating?
Potential benefits would be participants learning new coping strategies and techniques to manage psychological distress associated with their health condition, and also helping to improve quality of life in general. Another possible benefit of taking part would be meeting others with shared experiences of the same health condition in a supportive, small group environment. The researchers do not anticipate any direct risks or disadvantages of taking part in this study. However, they appreciate that talking about personal experiences could be upsetting and support from the research team will be available to all participants as well as the option to withdraw from the study at any time.

Where is the study run from?
Northern Care Alliance NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?
January 2022 to October 2023

Who is funding the study?
1. Bowel Research UK
2. Pseudo Obstruction Research Trust (PORT) (UK)

Who is the main contact?
Dr Holly Martin-Smith, holly.martinsmith@nca.nhs.uk

Contact information

Dr Holly Martin-Smith
Principal Investigator

Salford Royal Hospital
Stott Lane
Salford
M6 8HD
United Kingdom

ORCiD logoORCID ID 0000-0001-6585-8073
Phone +44 (0)161 206 5588
Email Holly.MartinSmith@nca.nhs.uk
Dr Sarah Kelly
Scientific

Intestinal Failure Unit
Salford Royal Hospital
Stott Lane
Salford
M6 8HD
United Kingdom

Phone 0161 206 5063
Email Sarah.Kelly@nca.nhs.uk
Dr Katherine Twist
Scientific

Department of Clinical Health Psychology
Clinical Sciences Building
Salford Royal Hospital
Stott Lane
Salford
M6 8HD
United Kingdom

ORCiD logoORCID ID 0000-0001-8138-8518
Phone +44 (0)161 206 5588/4250
Email Katherine.twist@nca.nhs.uk
Prof Simon Lal
Scientific

Intestinal Failure Unit (Ward H8)
Salford Royal Hospital
Stott Lane
Salford
M6 8HD
United Kingdom

ORCiD logoORCID ID 0000-0002-6245-8864
Phone +44 (0)161 206 5116
Email Simon.Lal@nca.nhs.uk
Dr John McLaughlin
Scientific

Salford Royal Hospital
Stott Lane
Salford
M6 8HD
United Kingdom

ORCiD logoORCID ID 0000-0001-6158-5135
Phone +44 (0)161 206 64047
Email John.Mclaughlin@nca.nhs.uk
Dr Peter Paine
Scientific

Salford Royal Hospital
Stott Lane
Salford
M6 8HD
United Kingdom

ORCiD logoORCID ID 0000-0003-4131-9651
Email Peter.Paine@nca.nhs.uk
Dr Michael Taylor
Scientific

Intestinal Failure Unit
Salford Royal Hospital
Stott Lane
Salford
M6 8HD
United Kingdom

Phone +44 (0)161 206 8059
Email Michael.taylor@nca.nhs.uk
Dr Calvin Heal
Scientific

School of Health Sciences
Faculty of Biology, Medicine and Health
The University of Manchester
Jean McFarlane Building
Manchester
M13 9PY
United Kingdom

ORCiD logoORCID ID 0000-0002-6445-1551
Phone +44 (0)161 206 4567
Email calvin.heal@manchester.ac.uk

Study information

Study designRandomized; Both; Design type: Treatment, Education or Self-Management, Psychological & Behavioural, Complex Intervention, Qualitative
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet 43022_PIS_V2_28Nov22.pdf
Scientific titleThe effectiveness of an acceptance and commitment therapy based psychological intervention on reducing psychological distress in those diagnosed with gastro-intestinal dysmotility
Study acronymThe PORT Study – ACTing on your GUT feelings
Study hypothesisAn acceptance and commitment therapy (ACT) group intervention will reduce psychological distress and increase health-related quality of life and psychological flexibility relative to a waiting list (treatment as usual) control condition in patients diagnosed with gastro-intestinal dysmotility.
Ethics approval(s)Approved 23/12/2022, North West- Greater Manchester East Research Ethics Committee (3rd Floor, Barlow House, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)2071048306; gmeast.rec@hra.nhs.uk), ref: 22/NW/0364
ConditionGastro-intestinal dysmotility
InterventionPotential participants will be invited into the study by invitation letter with an opt-in reply. Those interested will be given a participant information sheet explaining the rationale for the study and they will have the opportunity to ask questions before giving their consent to take part. Participants who are interested in taking part in the study will also have an assessment to ensure suitability for the group intervention. Those who require other mental health support/not suitable will be provided with information on how to access other available support. They will also be asked to complete several baseline questionnaires. Demographics: age, sex, marital status, ethnicity, and employment, previous/current psychology input, Psychological outcomes: Patient Health Questionnaire (PHQ-9) and General Anxiety Disorder (GAD-7) to assess depression and anxiety; Acceptance and Action Questionnaire (AQII) to assess psychological flexibility; previous psychology input, QOL: Short form 36 (SF36) Medical: gastrointestinal/HPN complications, HPN requirements, hospital readmissions, length of admissions, sick days, opioid use, and anti-depressant use. Once recruited, participants will be randomly allocated to either group intervention or waitlist control by random number sequence allocation. This will be a single-blind study design as participants will know whether they had been allocated to the group or not. Participants allocated to the group intervention will be put into a group of 9-10 people. The ACT intervention will be carried out in an online format over a period of 8 weeks with each session lasting approximately 2 hours. The intervention will utilise a standardised therapy manual based on ACT-based interventions but adapted to the patient population. It will cover a different topic each week but ultimately work on the ACT principles of becoming more open with emotions, aware of the present moment and engaged in working towards values important to them. Attendance will be recorded for the acceptability and feasibility part of the study and all group participants will be asked to complete a feedback form for each session attended of the intervention to assess effective components. A select number of those would also take part in a qualitative semi-structured interview based on their experiences of the group and the acceptability and feasibility of the intervention. Interviews will be expected to last about 1 hour. All participants regardless of the randomly allocated group will complete post-intervention measures.
Intervention typeBehavioural
Primary outcome measure1. Anxiety is measured using the Generalised Anxiety Disorder (GAD7) questionnaire at baseline, week 7 and week 15
2. Depression is measured using the Patient Health Questionnaire (PHQ9) at baseline, week 7 and week 15
3. Psychological flexibility is measured using the Acceptance and Action Questionnaire (AQII) at baseline, week 7 and week 15
4. Health-related quality of life (HRQoL) is measured using the RAND 36-item Health Survey 1.0 (SF-36) at baseline, week 7 and week 15
Secondary outcome measures1. Demographics (age, sex, marital status, ethnicity, employment, diagnosis, duration of diagnosis and previous psychology input) are measured using a questionnaire at baseline
2. Medical outcomes (gastrointestinal/HPN complications, HPN requirements, hospital readmissions, opioid use, anti-depressant use) are measured using access to medical records at baseline and week 15
Overall study start date02/01/2022
Overall study end date31/10/2023

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsPlanned Sample Size: 50; UK Sample Size: 50
Total final enrolment6
Participant inclusion criteria1. Has a diagnosis of GID
2. Age 18 years or above
3. Is fluent in English
Participant exclusion criteria1. Insufficiently well to give consent or to take part
2. Currently receiving or due to start psychological therapy at another service or privately
3. Difficulties such that they are currently in receipt of ongoing input from secondary care mental health services
4. Substantial substance abuse difficulties
5. Severe and/or chronic mental health problems such as personality disorders where the interpersonal difficulties themselves are the required focus of an intervention
6. A learning disability, at such a level that specialist skills would be required to deliver an intervention
Recruitment start date07/03/2023
Recruitment end date31/05/2023

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Salford Royal Hospital
Stott Lane
Eccles
Salford
M6 8HD
United Kingdom

Sponsor information

Northern Care Alliance NHS Foundation Trust
Hospital/treatment centre

Salford Royal
Research and Innovation Department
Stott Lane
Salford
M6 8HD
England
United Kingdom

Phone +44 (0)1612065583
Email RDResearch@nca.nhs.uk

Funders

Funder type

Charity

Bowel Research UK
Government organisation / Trusts, charities, foundations (both public and private)
Alternative name(s)
Bowel Research United Kingdom, BRUK
Location
United Kingdom
Pseudo Obstruction Research Trust

No information available

Results and Publications

Intention to publish date31/10/2024
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryData sharing statement to be made available at a later date
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal
IPD sharing planThe data-sharing plans for the current study are unknown and will be made available at a later date

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet version 2 28/11/2022 18/01/2023 No Yes
Protocol file version 2 28/11/2022 18/01/2023 No No
HRA research summary 28/06/2023 No No

Additional files

43022_PIS_V2_28Nov22.pdf
43022_PROTOCOL_V2_28Nov22.pdf

Editorial Notes

31/10/2024: Contact details updated, total final enrolment added.
03/03/2023: The sponsor was updated.
14/02/2023: The recruitment start date was changed from 14/02/2023 to 07/03/2023.
11/01/2023: Trial's existence confirmed by the NIHR.